PEDIATRICS Vol. 102 No. 6 December 1998, pp. 1483-1491

AMERICAN ACADEMY OF PEDIATRICS:
Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine

Committee on Infectious Diseases

	ABSTRACT

Top Abstract Recommendation References

Virtually all children experience rotavirus (Rv) infection before school entry. In the United States and other temperate countries, Rv disease peaks in the winter and during this time is responsible for the majority of episodes of diarrhea in infants and young children.^1-4 Data collected by the Centers for Disease Control and Prevention from 1979 through 1992 indicate that approximately 50 000 hospitalizations attributable to Rv occur annually in the United States, a number that approximates about 1 in 78 children being hospitalized with Rv diarrhea by 5 years of age.^2,5

RotaShield (Wyeth-Lederle Vaccines and Pediatrics, Philadelphia, PA) was licensed by the Food and Drug Administration on August 31, 1998, for oral administration to infants at 2, 4, and 6 months of age. The rationale for using Rv immunization for prevention or modification of Rv disease is based on several considerations. First, the rate of illness attributable to Rv among children is comparable in industrialized and developing countries, which indicates that improved public sanitation is unlikely to decrease the incidence of disease.^6,7 Second, although implementation of oral rehydration programs to prevent dehydration has improved in the United States, widespread use is inadequate to prevent significant morbidity.^8-11 Third, trials of rhesus rotavirus-tetravalent (Rv) vaccine in the United States, Finland, and Venezuela show efficacy rates of approximately 80% for prevention of severe illness and 48% to 68% against Rv-induced diarrheal episodes.^12-16 These results are similar to the protection observed after natural Rv infection, which also confers better protection against subsequent episodes of severe disease than against mild illness.^17-19 This statement provides recommendations regarding the use of Rv vaccine in infants in the United States.

	EPIDEMIOLOGY OF ROTAVIRUS INFECTION

Rotavirus (Rv) is present in high concentrations in stools of infected children and may be excreted 2 days before and as many as 10 days after onset of symptoms in immunocompetent hosts.²⁰ Rv can persist on fomites that may serve as reservoirs for infection, which is especially important in child care centers.²¹ Transmission occurs by the fecal-oral route, and common source outbreaks with person-to-person transmission have been reported.^22,23 Data proving transmission by other routes are lacking. The incubation period is usually 1 to 3 days. Rv infections occur in many animals but animal-to-human transmission has not been documented.²⁴

Various epidemiologic studies have estimated that Rv causes greater than 3 million cases of diarrhea, 50 000 hospitalizations, and 20 to 40 deaths annually in the United States.^3,525-28 The peak incidence of Rv infection in the United States and other temperate countries occurs in winter, with early activity in the southwest late in the fall and progressive geographic and temporal movement of activity to the northeast and east.^3,4,29 More than 50% of diarrheal episodes requiring in-hospital care during the peak of the winter Rv season is attributable to Rv disease; virtually all children will have had at least one Rv infection by 4 years of age.^1,2530-33 Disease tends to be most severe between 3 and 24 months of age, although 25% of the cases of severe disease occur after 2 years of age.⁵ Infants younger than 3 months of age are relatively protected against Rv disease; breastfeeding and transplacental antibody may decrease the likelihood and severity of infection.^1734-36 Infections in neonates generally are asymptomatic.¹⁷

The incidence of Rv disease in countries 10 degrees above or below the equator is less seasonal than in temperate countries.³⁷ Worldwide, Rv is estimated to cause more than 125 million cases of diarrhea annually in children younger than 5 years of age. Eighteen million cases are considered at least moderately severe, with approximately 600 000 deaths per year.⁷

Because the clinical features and stool characteristics of diarrhea caused by Rv are nonspecific, confirmation of the diagnosis of Rv infection in children with diarrhea by laboratory testing is necessary in some clinical settings and surveillance activities. The most frequently used method is antigen detection in stool by enzyme immunoassay (EIA) directed at a group antigen common to all group A Rvs, including those in the Rv vaccine. Stool specimens from children immunized with Rv vaccine may test positive by EIA for several weeks after immunization.

	CLINICAL MANIFESTATIONS

Primary Rv infection of infants and toddlers may be asymptomatic or result in diarrhea, usually preceded or concomitant with emesis and fever. In one study of 72 hospitalized patients with proven Rv infection, emesis and a temperature greater than 37.8°C occurred in 96% and 77% of patients, respectively.³⁰ Accompanying dehydration usually is isotonic and can be severe with concomitant acidosis. Infection also can be associated with upper respiratory tract symptoms, such as coryza and cough. Neurologic symptoms occur in severe cases and may be attributable to electrolyte imbalance or central nervous system involvement.³⁸ Second episodes are common and generally mild or asymptomatic, but severe illness does occur during reinfection.^{17,19,20,23,39,40} Infection of children with significant T-lymphocyte abnormalities such as those associated with severe combined immune deficiency can result in a persistent infection associated with multisystem abnormalities, particularly hepatic and renal involvement.^41,42 Data indicate that the majority of deaths attributable to diarrhea in the United States occurs in premature infants,⁴³ but data specifically linking death and Rv infection are not available.

	IMMUNITY

Protective Efficacy After Natural Infection

Children may be infected with Rv several times during their lives.^{17,19,23,44,45} After an initial natural infection, 38%, 77%, and 87% of children are protected against any subsequent infection, diarrhea, and severe diarrhea, respectively.¹⁹ The components of the immune response necessary to provide protection against Rv have not been completely defined. Rv-specific fecal and salivary immunoglobulin A (IgA), serum IgA and immunoglobulin G (IgG), G type-specific antibody, and cell-mediated immunity reflect natural infection and illness.^46-49 In adult volunteers, prospectively monitored children, and animal models, preexisting serum antibody and fecal Rv IgA antibody have been associated with protection against infection or disease.^1846-50 Antibody responses to first infections are primarily homotypic (to the infecting G type); antibody responses to subsequent infections are broader and reflect a heterotypic response.⁵¹

Immunologic Correlates of Protection in Vaccine Studies

Studies have demonstrated variable associations between serum Rv antibody concentrations and protection.^52-54 Specificity of Rv-neutralizing antibodies after Rv immunization has not correlated with protection.^52,53 Studies that evaluate homotypic and heterotypic epitope-specific antibody responses may provide clarification.⁵¹

	EFFECT OF ORAL REHYDRATION

Oral rehydration therapy has been recommended by both the American Academy of Pediatrics (AAP)¹⁰ and the Centers for Disease Control and Prevention (CDC)⁹ for prevention and treatment of dehydration resulting from diarrhea in infants and children, but oral rehydration is underutilized in the United States.⁸ The principles of oral rehydration therapy include early adequate rehydration using an appropriate solution, replacement of ongoing fluid losses from vomiting and diarrhea with oral rehydration solution (ORS), and frequent feeding as soon as dehydration is corrected. Early initiation of oral rehydration therapy in children with diarrhea reduces morbidity and mortality associated with diarrhea and dehydration in children. Most children with diarrhea should receive an appropriate ORS.¹¹

	PREVENTION

Vaccine

Initial vaccine candidates, developed in the 1980s, were monovalent vaccines derived from animal strains. These vaccines were tested under different conditions and efficacy results were inconsistent from trial to trial.^6,55

The recently licensed vaccine is a live-attenuated orally administered product derived from four group A Rvs. Three of the Rvs are single gene reassortants of the VP7 gene of human origin (types G1, G2, and G4); the fourth strain is rhesus Rv (type G3), which is antigenically similar to human G3. This quadrivalent vaccine formulation contains one unaltered rhesus Rv strain and three reassortant strains. Each reassortant contains the gene encoding the G protein of its parent human Rv and the remaining 10 genes are from the parent rhesus Rv.^55,56

Manufacturing, handling, and storage. Each dose of the Rv vaccine is given orally as a 2.5-mL volume that contains approximately 1 × 10⁵ plaque-forming units (PFU) of each of the four strains. The viruses are grown in a fetal rhesus diploid cell line. Fetal bovine serum from US herds free of bovine spongiform encephalitis, neomycin sulfate, amphotericin B, and monosodium glutamate are present during cell culture growth. This vaccine is supplied in single-dose vials as a lyophilized preparation with one pouch of buffer diluent for reconstitution containing 9.6 mg/mL of citric acid and 25.6 mg/mL of sodium bicarbonate to neutralize stomach acidity and protect the acid-labile virus from inactivation.⁵⁷ Neither vaccine nor diluent contains preservatives. Before reconstitution, the vaccine is stable for at least 24 months when stored between 2°C and 25°C (36°C and 77°F). Once reconstituted, the vaccine is stable for at least 60 minutes at room temperature (23°C to 27°C; 73°F to 81°F) and at least 4 hours when refrigerated at 2°C to 8°C (36°F to 46°F), after which the reconstituted product should be discarded. To maintain potency, the lyophilized vaccine and diluent should be stored at temperatures between 2°C and 27°C (36°F and 81°F). The lyophilized vaccine and the diluent should not be frozen.

Administration, dosage, and schedule. This Rv vaccine is recommended by the manufacturer for oral administration to infants at 2, 4, and 6 months of age. Each dose should be separated from another dose by at least 3 weeks, and all three doses should be administered by 6 months of age. According to the product label, administration as late as 12 months of age is acceptable if at least one dose has been given between 6 weeks and 6 months of age. Administration of the first dose of vaccine to children older than 6 months of age may result in a higher rate of fever and is not recommended currently.^12,14,15 A period between doses of longer than 2 months is not an indication for restarting the three-dose series. Insufficient safety and efficacy data are available to support administration of Rv vaccine to children older than 12 months of age. Because the safety of administering a dose of vaccine higher than the recommended dose is not known, a second dose of vaccine should not be administered to an infant who vomits or spits up during or after administration of Rv vaccine. The infant should receive the remaining doses of vaccine according to the recommended schedule.

Immunogenicity. Studies of Rv vaccine demonstrate that more than 88% of children respond to three doses of the vaccine as indicated by either a fourfold or greater rise in serum IgA titers as measured by either EIA or neutralizing antibody assays to vaccine strains (Table 1).^12-16 In Venezuela, the number of responses after the third vaccine dose was not significantly different from that after 2 doses.¹⁵ Children in the placebo groups of the studies had IgA antibody responses ranging from 4% to 29% after the third placebo dose,^12-16 indicating exposure to wild-type Rv during the course of these studies.

Efficacy. Studies with Rv vaccine containing 4 × 10⁵ PFU^13-16 or 4 × 10⁴ PFU¹² involving more than 3000 children in the United States, Finland, and Venezuela demonstrated efficacy rates of 48% to 68% in preventing diarrhea caused by Rv, 38% to 91% in preventing moderate disease, and 70% to 100% in preventing severe disease (Table 2).^12-16 In Venezuela Rv vaccine prevented dehydration and hospitalization in 75% and 70% of recipients, respectively; in Finland rates of prevention of dehydration and hospitalization were 97% and 100%, respectively. In Finland the protective rate against physician visits, hospital outpatient clinic visits, diarrhea more than 5 days, vomiting more than 2 days, a temperature above 39°C, and acidosis was greater in the vaccine group when compared with the placebo group (P < .001). In a US trial, none of the children in the vaccine group compared with 13 of 385 (3%) children in the placebo group became dehydrated.¹³ In this same study, physician intervention occurred for 16 of 398 (4%) children in the vaccine group and 58 of 385 (15%) in the placebo group (73% efficacy, 95% confidence interval [CI] 54,84). In a second US study, medical visits for diarrhea and vomiting occurred for 27 (9%) children in the placebo group compared with 6 (2%) in the vaccine group (78% efficacy, 95% CI 38,93).¹²

In several of the studies, episodes of rotaviral diarrhea were serotyped.^12-15 Most of these wild-type Rv strains were of the G1 serotype and, therefore, several studies could not determine the efficacy of the vaccine against other serotypes of Rv.^12,13,15 In one US study, the vaccine was protective against G3, which was the predominant serotype.¹⁶ In the study conducted in Finland, protection against G1 serotype (70%, 95% CI 58% to 78%) was similar to protection against the G4 serotype (76%, 95% CI 29% to 92%).¹⁴ No data are available to indicate whether this Rv vaccine protects against diarrhea attributable to rotavirus strains not contained in the vaccine.

Duration of protection. In Finland Rv vaccine was 68% effective in preventing rotaviral diarrhea and 90% effective for prevention of severe disease during two seasons of surveillance.¹⁴ Vaccine efficacy was greater during the first than during the second analysis period.¹⁴

Effect of breastfeeding on immunogenicity. Although breastfeeding has been demonstrated to decrease the immunogenicity of single doses of Rv vaccine,⁵⁸ no overall effect has been noted on immune response or efficacy after administration of 3 doses of Rv vaccine.⁵⁹

Adverse effects. Approximately 10 000 infants 6 to 28 weeks of age have received rhesus Rv vaccine at doses ranging from 4 × 10⁴ to 4 × 10⁶ PFU,^12-1660-63 including approximately 3200 infants who received Rv vaccine in five placebo-controlled studies.^12-16 The Rv vaccine appears to be safe at doses of 4 × 10⁴ PFU¹² and 4 × 10⁵ PFU (Table 3).^13-16 The major side effects reported in the five placebo-controlled trials were an increase in temperature 38°C, an increase in temperature >39°C, decreased appetite, irritability and decreased activity, all of which occurred more often in the immunized infants than in the placebo group during the first 3 to 5 days after the first dose^12,14,15 (Table 3). Temperature >38°C was observed more frequently in immunized infants than in placebo recipients in the 5 days after the second dose of vaccine. No significant differences were demonstrated between the vaccine and placebo groups in the occurrence of vomiting, coughing, rhinitis, or other clinical signs or symptoms in these studies.^12,14,15 In the one US study in which serum alanine aminotransferase levels were measured, no difference was demonstrated between the two groups.¹² In all five studies no significant differences were noted in side effects between the two groups after the third dose of vaccine or placebo.^12-16

In all studies of Rv vaccines involving more than 10 000 children, 5 cases of intussusception were identified in children receiving vaccine on days 6 through 51 after doses 2 or 3, and 1 case among placebo recipients.⁶⁴ The difference in rates was not significant and did not exceed the expected background rate in the community. In the US multicenter trials, no significant difference in growth retardation was demonstrated in children who received the vaccine compared with those who received the placebo.

Data regarding immunization of premature infants are limited but important, because morbidity and mortality from diarrhea in general appear to be increased in this group.²⁸ Of 23 infants who were 35 weeks of gestation who received Rv vaccine, 1 developed fever (38.6°C) on day 2 and 2 developed diarrhea between days 2 to 5 and 6 to 12 after immunization.

Reporting adverse events. Serious adverse events that occur after administration of Rv vaccine should be described in the patient's medical record and reported to the Vaccine Adverse Events Reporting System (VAERS) by calling 800-822-7967 or via the World Wide Web at http://www.cdc.gov/nip/vaers.htm.

Contraindications and precautions for administration. Because Rv vaccine contains live Rv, this vaccine should not be administered to children known to be immunocompromised because of congenital immunodeficiency including combined immunodeficiency, hypogammaglobulinemia, agammaglobulinemia, thymic abnormalities, or to those with human immunodeficiency virus (HIV) infection, even though diarrhea attributable to Rv infection or complications of natural Rv infection in children who are HIV-positive are no greater than those in infants who are HIV-negative.⁶⁵ In addition, the vaccine is not approved by the Food and Drug Administration (FDA) for use in children with solid organ or hematopoetic malignancies or advanced debilitating conditions or in children receiving immunosuppressive therapy or radiation and children who are immunocompromised because of hematopoetic or solid organ transplantation. The presence of an immunocompromised family member in the same home as an infant scheduled to be immunized is not a contraindication to vaccine administration. Hypersensitivity to any component of the vaccine including aminoglycoside antibiotics, amphotericin B, or monosodium glutamate is a contraindication to administration.

Children who have acute vomiting or diarrhea should not receive Rv vaccine because the immunogenicity and efficacy have not been established in children with these conditions. Rv infection may be more severe in children with chronic gastrointestinal tract disease including short gut syndrome, Hirschsprung's disease, and congenital malabsorption syndrome, but data evaluating the immunogenicity, safety, and efficacy of this Rv vaccine in these populations of children are not available. Mild upper respiratory tract infections with or without low-grade fever are not contraindications to immunization. Data are not available regarding administration of this Rv vaccine to infants who have received an immune globulin-containing product parenterally within the past several months; however, data from studies of other orally administered live vaccines indicate that simultaneous administration with immune globulin-containing products does not affect the immunogenicity of the vaccines. Health care professionals with latex sensitivity who administer the vaccine should do so with caution because the packaging contains dry natural rubber.

Transmission of Rv vaccine strains. This Rv vaccine consists of live Rv that replicates in the intestine of the recipient and is shed in stool.^15,66 The documented rate of excretion of Rv in stool depends on the method of detection; polymerase chain reaction (PCR) is more sensitive than EIA, electron microscopy, or polyacrylamide-gel electrophoresis. Although Rv shedding was detected in stool specimens from 125 of 248 (50%) children in eight centers in the United States,⁶⁶ studies in child care centers⁶⁷ have not demonstrated transmission of vaccine strains from vaccine recipients to nonrecipients. In Venezuela with PCR, cell culture, and electrophoresis used to test stool specimens, a vaccine strain was detected in 29 (14%) of the 213 Rv-positive stool specimens from children with diarrhea. Eighteen of the 139 episodes of diarrhea in the placebo group (13%) and 11 of 74 episodes in the vaccine group (15%) yielded a vaccine strain. In all of these episodes the vaccine strain occurred in conjunction with a wild-type Rv strain, indicating that the vaccine strain alone did not cause diarrhea. In addition, the vaccine strains were not detected in stools by EIA,¹⁵ indicating that the virus was shed in low titer.

Administration with other vaccines. Studies evaluating the concomitant administration of this Rv vaccine with oral poliovirus vaccine (OPV), inactivated poliovirus vaccine (IPV), Haemophilus influenzae type b vaccine (Hib), diphtheria and tetanus toxoids and pertussis (DTP), and hepatitis B virus vaccines have demonstrated no effect on the immune response to any of the antigens in these vaccines.^68,69 Infants given OPV concurrently with Rv vaccine may have slightly decreased serum antibody responses to Rv antigens and serotype 1 poliovirus, but this possible interference is not evident after 3 doses of Rv and polio vaccines.⁶⁸

Immunization after documented disease. Children with documented Rv infection should complete their Rv immunization schedule because one natural infection may not confer protection against all serotypes of Rv that cause disease.¹⁹

	ECONOMIC IMPACT OF RV DISEASE

In cost-benefit analyses of Rv vaccines, the cost of the vaccine and rates of hospitalization, emergency department (ED) visits, and physician visits contribute to direct medical costs, while time lost from work by parents and other caregivers contribute to societal costs. The cost-effectiveness of giving Rv vaccine to infants in the United States at 2, 4, and 6 months of age has been analyzed in several studies.^26,27,70

The study by Tucker and associates²⁷ used the most recent assumptions for vaccine efficacy and disease burden. On the basis of a birth cohort of 3.9 million, the authors estimated that annually, Rv results in 50 000 hospitalizations of children between birth and 5 years of age, with a length of hospitalization of 3.4 days, 160 000 ED visits at a cost of $243 per case, and 410 000 physician visits at a cost of $132 per visit. The Rv vaccine was estimated to have an efficacy of 85% against hospitalizations and deaths, 75% against ED visits, and 70% against physician visits. No correction was made for possible herd immunity or for severe adverse effects. With this study, a national Rv immunization program in which 3 doses of this Rv vaccine administered at 2, 4, and 6 months of age would result in 1.08 million fewer episodes of diarrhea, 227 000 fewer physician visits, 95 000 fewer ED visits, 34 000 fewer hospitalizations, and 13 fewer deaths during the first 5 years of life. This decrease would be cost-effective, yielding savings in direct medical costs (primarily the cost of hospitalization) and nonmedical costs (primarily the loss of caregiver earnings), depending on the price of the vaccine. If a different rate of hospitalization is used in these calculations or the variables used are altered, the cost-benefit analysis would be affected.

	FACTORS THAT MAY INFLUENCE VACCINE ACCEPTANCE

Many enteric pathogens other than Rv are associated with diarrhea and vomiting. Because children in the United States may have as many as 8 episodes of diarrhea in the first 5 years of life, parents may not appreciate the true impact of the Rv vaccine. The impact should be apparent to office-based pediatricians who may see a decrease in the number of children with office visits for watery diarrhea. In addition, because Rv accounts for approximately 50% of hospitalizations from diarrhea and dehydration during the winter Rv season and because the vaccine is 80% or more effective in preventing these illnesses, a substantial reduction should occur in serious diarrhea and dehydration after widespread use of this vaccine. Similar to many vaccines the magnitude of reduction in disease may need to be realized from aggregative data.

	RECOMMENDATIONS

Top Abstract Recommendation References

Morbidity from Rv disease in the United States and cost to the health care system and society associated with Rv disease are substantial. These considerations in conjunction with vaccine safety and efficacy justify a nationwide immunization program for prevention or modification of Rv disease in infants and young children. Specific AAP recommendations for use of this FDA-approved Rv vaccine are as follows:

1. Based on safety and efficacy data, Rv vaccine is recommended for use in infants at 2, 4, and 6 months of age for prevention of Rv disease; routine implementation of this recommendation will require reconciliation of related economic issues.
2. The first dose of Rv vaccine may be given to infants as early as 6 weeks of age. For children in whom initiation of vaccine has been delayed, the first dose may be given as late as 6 months of age. Each subsequent dose should be given at an interval of at least 3 weeks. Special efforts should be made to immunize infants before the anticipated annual onset of Rv disease activity in their local communities.
3. Increased rates of fever have been reported in vaccine recipients after the first and second doses, but fevers generally are mild and last less than 24 hours. Initiation of immunization after 6 months of age is not recommended because of the age-related occurrence of fever after receipt of the first dose of vaccine. All three doses of vaccine should be administered during the first 12 months of age because data regarding the safety and efficacy of vaccine administration to older children are not available.
4. The Rv vaccine can be administered at the same time as DTaP (or DTP), Hib, hepatitis B, or IPV/OPV vaccines as recommended in the routine immunization schedule. Modification of timing of administration of Rv vaccine is not necessary after administration of antibody-containing blood products, including blood, plasma, and immune globulin.
5. To ensure maximum immunity, the recommended three-dose Rv immunization schedule should be completed even if a child has had a documented episode of wild-type Rv gastroenteritis.
6. Contraindications to Rv vaccine include the following:
   • Infants with hypersensitivity to aminoglycoside antibiotics, amphotericin B, or monosodium glutamate that are components of the vaccine, should not receive this vaccine. In addition, Rv vaccine should not be administered to persons who have experienced an anaphylactic reaction to a previous dose of Rv vaccine.
   • Infants with moderate or severe febrile illness should not receive the Rv vaccine during the illness, but should be immunized as soon as they have recovered from the acute phase of their illness. The Rv vaccine, like other vaccines, can be given to infants with a low-grade fever.
   • Until further data are available, children who are known or suspected to be immunosuppressed or immunodeficient should not receive this live-attenuated virus vaccine. The vaccine should not be administered to infants born to women known to be HIV-infected until tests for HIV infection in the infant are negative at 2 months or older by PCR or culture.⁷¹ Infants living in households with persons known or suspected to be immunocompromised should be immunized.
7. Breastfeeding is not a contraindication to administration of Rv vaccine.
8. This Rv vaccine is not recommended for children with acute vomiting or diarrhea because vaccine efficacy in these circumstances has not been established. Consideration should be given to immunizing children with chronic gastrointestinal tract disease until further data are available to make definitive recommendations for this group.
9. Although data are limited, premature infants may receive Rv vaccine at or after discharge from the hospital nursery if they have achieved a chronologic age of at least 6 weeks.
10. If a child is hospitalized after administration of Rv vaccine, he/she can be managed by standard precautions and does not need to be placed in contact precautions unless diarrhea, vomiting, or both occur. Children may attend their child care facilities after administration of Rv vaccine.

	RESEARCH NEEDS AND FUTURE DEVELOPMENTS

Studies are needed to define more fully the serologic parameters that can be used to predict whether a candidate Rv vaccine will be efficacious. Other candidate Rv vaccines are in different stages of testing and may be approved for use in children in the future.⁷² Once any Rv vaccine is introduced, postlicensure surveillance is necessary to define the incidence of rotaviral diarrhea, including monitoring the projected decline in the number of cases of Rv disease and hospitalizations after a Rv vaccine has been introduced to evaluate the cost savings of the vaccine program, to assess potential changes in serotypes associated with disease, to determine if new or unusual strains emerge, and to evaluate adverse effects.

Because none of the clinical trial data extend beyond 2 years, duration of protection beyond this time is uncertain, but protection similar to that after natural infection is expected. Data are needed to establish the safety, immunogenicity, and, if possible, efficacy of the Rv vaccine, and of future Rv vaccines in several populations, including premature infants and children with acute diarrhea, chronic gastrointestinal tract disease, immunosuppression; children in long-term care facilities; and children ages 1 to 3 years. Studies also are needed to determine the efficacy of a two-dose immunization schedule as well as the effect of maternal Rv immunization on maternal milk and serum antibody titers and the protection afforded to nursing infants by these maternal antibodies.⁷³ The long-term goal of the Rv vaccine program is to prevent rotaviral disease. These recommendations are important steps in achieving this goal.

COMMITTEE ON INFECTIOUS DISEASES, 1998-1999
Neal A. Halsey, MD, Chairperson
Jon S. Abramson, MD
P. Joan Chesney, MD
Margaret C. Fisher, MD
Michael A. Gerber, MD
S. Michael Marcy, MD
Dennis L. Murray, MD
Gary D. Overturf, MD
Charles G. Prober, MD
Thomas N. Saari, MD
Leonard B. Weiner, MD
Richard J. Whitley, MD

EX-OFFICIO
Carol Baker, MD
Georges Peter, MD
Larry K. Pickering, MD

LIAISON REPRESENTATIVES
Anthony Hirsch, MD
AAP Council on Pediatric Practice
Richard F. Jacobs, MD
American Thoracic Society
Noni E. MacDonald, MD
Canadian Paediatric Society
Ben Schwartz, MD
Centers for Disease Control and Prevention
Walter A. Orenstein, MD
Centers for Disease Control and Prevention
M. Carolyn Hardegree, MD
Food and Drug Administration
N. Regina Rabinovich, MD
National Institutes of Health
Robert F. Breiman, MD
National Vaccine Program Office

	FOOTNOTES

The recommendations in this statement do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

	ABBREVIATIONS

Rv, rotavirus infection; EIA, enzyme immunoassay; IgA, immunoglobulin A; IgG, immunoglobulin G; AAP, American Academy of Pediatrics; CDC, Centers for Disease Control and Prevention; ORS, oral rehydration solution; PFU, plaque-forming units; CI, 95% confidence interval; VAERS, Vaccine Adverse Events Reporting System; HIV, human immunodeficiency virus; FDA, Food and Drug Administration; PCR, polymerase chain reaction; OPV, oral poliovirus vaccine; IPV, inactivated poliovirus vaccine; Hib, Haemophilus influenzae type b vaccine; DTP, diphtheria and tetanus toxoids and pertussis; ED, emergency department; DTaP, diphtheria and tetanus toxoids and acellular pertussis.

	REFERENCES

Top Abstract Recommendation References

1. Brandt CD, Kim HW, Rodriguez JO, Pediatric viral gastroenteritis during eight years of study. J Clin Microbiol 1983; 18:71-78 [Abstract/Free Full Text]
2. Glass RI, Kilgore PE, Holman RC, The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996; 174(suppl 1):S5-S11
3. Jin S, Kilgore PE, Holman RC, Trends in hospitalizations for diarrhea in United States children from 1979 through 1992: estimates of the morbidity associated with rotavirus. Pediatr Infect Dis J 1996; 15:397-404 [CrossRef][Medline]
4. Torok TJ, Kilgore PE, Clarke MJ, Visualizing geographic and temporal trends in rotavirus activity in the United States, 1991 to 1996. Pediatr Infect Dis J. 1997; 16:941-946 [CrossRef][Medline]
5. Parashar UD, Holman RC, Clarke MJ, Bresee JS, Glass RI Hospitalizations associated with rotavirus diarrhea in the United States, 1993 through 1995: surveillance based on the new ICD-9-CM rotavirus specific diagnostic code. J Infect Dis 1998; 177:13-17 [Medline]
6. Midthun K, Kapikian AZ Rotavirus vaccines: an overview. Clin Microbiol Rev. 1996; 9:423-434 [Abstract]
7. Bern C, Martines J, de Zoysa I, Glass RI The magnitude of the global problem of diarrhoeal disease: a ten year update. Bull WHO 1992; 70:705-714 [Medline]
8. Avery ME, Synder JD Oral therapy for acute diarrheathe underused simple solution. N Engl J Med 1990; 323:891-894 [Medline]
9. Duggan C, Santosham M, Glass RI. The management of acute diarrhea in children: oral rehydration, maintenance, and nutritional therapy. MMWR Morb Mortal Wkly Rep. 1992;41(RR-16):1-20
10. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis Practice parameter: the management of acute gastroenteritis in young children. Pediatrics 1996; 97:424-435 [Abstract/Free Full Text]
11. Santosham M, Keenan EM, Tulloch J, Broun D, Glass R. Oral rehydration therapy for diarrhea: an example of reverse transfer of technology. Pediatrics. 1997;100(5). URL: http://www.pediatrics.org/cgi/content/full/100/5/e10
12. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA, US Rotavirus Vaccine Efficacy Group Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995; 273:1191-1196 [Abstract/Free Full Text]
13. Rennels MB, Glass RI, Dennehy PH, Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccinesreport of the National Multicenter Trial. Pediatrics 1996; 97:7-13 [Abstract/Free Full Text]
14. Joensuu J, Koskenniemi E, Pang XL, Vesikari T Randomized placebo-controlled trial of rhesus human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350:1205-1209 [CrossRef][Medline]
15. Perez-Schael I, Guntinas MJ, Perez M, Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337:1181-1187 [Abstract/Free Full Text]
16. Santosham M, Moulton LH, Reid R, Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131:632-638 [CrossRef][Medline]
17. Bishop RF, Barnes GL, Cipriani E, Lund JS Clinical immunity after neonatal rotavirus infection: a prospective longitudinal study in young children. N Engl J Med 1983; 309:72-76 [Abstract]
18. Bishop R, Lund J, Cipriani E, Clinical serological and intestinal immune responses to rotavirus infection of humans. Med Virol 1990; 9:85-109
19. Velazquez FR, Matson DO, Calva JJ, Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-1028 [Abstract/Free Full Text]
20. Pickering LK, Bartlett AV III, Reves RR, Morrow A Asymptomatic excretion of rotavirus before and after rotavirus diarrhea in children in day care centers. J Pediatr 1988; 112:361-365 [CrossRef][Medline]
21. Wilde J, Van R, Pickering L, Eiden J, Yolken R Detection of rotaviruses in the day care environment by reverse transcriptase polymerase chain reaction. J Infect Dis 1992; 166:507-511 [Medline]
22. Pickering LK, Evans DG, DuPont HL, Vollett JJ, Evans DJ Diarrhea caused by Shigella, rotavirus and Giardia in day care centers: prospective study. J Pediatr 1981; 99:51-56 [CrossRef][Medline]
23. O'Ryan ML, Matson DO, Estes MK, Bartlett AV, Pickering LK Molecular epidemiology of rotavirus in children attending day care centers in Houston. J Infect Dis 1990; 162:810-816 [Medline]
24. Gentsch JR, Woods PA, Ramachandran M, Review of G and P typing results from a global collection of strains: implications for vaccine development. J Infect Dis 1996; 174(suppl 1):S30-S36
25. Matson DO, Estes MK Impact of rotavirus infection at a large pediatric hospital. J Infect Dis 1990; 162:598-604 [Medline]
26. Smith JC, Haddix AC, Teutsch SM, Glass RI Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995; 96:609-615 [Abstract/Free Full Text]
27. Tucker AW, Bresee JS, Haddix AC, Holman RC, Glass RI Cost-effectiveness analysis of a rotavirus vaccine program in the United States. JAMA 1998; 279:1371-1376 [Abstract/Free Full Text]
28. Kilgore PE, Holman RC, Clarke MJ, Glass RI Trends of diarrheal disease-associated mortality in US children, 1968 through 1991. JAMA 1995; 274:1143-1148 [Abstract/Free Full Text]
29. LeBaron CW, Lew J, Glass RI, Weber JM, Ruiz-Palacios GM Annual rotavirus epidemic patterns in North America: results of a five-year retrospective survey of 88 centers in Canada, Mexico, and the United States. JAMA 1990; 264:983-988 [Abstract/Free Full Text]
30. Rodriguez WJ, Kim HW, Arrobio JO, Clinical features of acute gastroenteritis associated with human reovirus-like agent in infants and young children. J Pediatr 1977; 91:188-193 [CrossRef][Medline]
31. Rodriguez WJ, Kim HW, Brandt CD, Rotavirus gastroenteritis in the Washington, DC area: incidence of cases resulting in admission to the hospital. Am J Dis Child 1980; 134:777-779 [Abstract/Free Full Text]
32. Gurwith M, Wenman W, Gurwith D, Brunton J, Feltham S, Greenberg H Diarrhea among infants and young children in Canada: a longitudinal study in three northern communities. J Infect Dis 1983; 147:685-692 [Medline]
33. Gurwith M, Wenman W, Hinde D, Feltham S, Greenberg H A prospective study of rotavirus infection in infants and young children. J Infect Dis 1981; 144:218-224 [Medline]
34. Duffy LC, Riepenhoff-Talty M, Byers TE, Modulation of rotavirus enteritis during breast feeding: implications on alterations in the intestine bacterial flora. Am J Dis Child 1986; 140:1164-1168 [Abstract/Free Full Text]
35. Newburg DS, Peterson JA, Ruiz-Palacios GM, Role of human-milk lactadherin in protection against symptomatic rotavirus infection. Lancet 1998; 351:1160-1164 [CrossRef][Medline]
36. Ramachandran M, Vij A, Kumar R, Lack of maternal antibodies to P serotypes may predispose neonates to infections with unusual rotavirus strains. Clin Diag Lab Immunol 1998; 5:527-530 [Abstract/Free Full Text]
37. Cook SM, Glass RI, LeBaron CW, Ho MS Global seasonality of rotavirus infections. Bull WHO 1990; 68:171-177 [Medline]
38. Ushijima H, Xin KQ, Nishimura S, Morikawa S, Abe T Detection and sequencing of rotavirus VP7 gene from human materials (stools, sera, cerebrospinal fluids, and throat swabs) by reverse transcription and PCR. J Clin Microbiol 1994; 32:2893-2897 [Abstract/Free Full Text]
39. Velazquez FR, Calva JJ, Guerrero ML, Cohort study of rotavirus serotype patterns in symptomatic and asymptomatic infections in Mexican children. Pediatr Infect Dis J 1993; 12:54-61 [Medline]
40. Rodriguez WJ, Kim HW, Brandt CD, Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J 1987; 6:170-176 [Medline]
41. Saulsbury FT, Winkelstein JA, Yolken RH Chronic rotavirus infection in immunodeficiency. J Pediatr 1980; 97:61-65 [CrossRef][Medline]
42. Gilger MA, Matson DO, Conner ME, Rosenblatt HM, Finegold MF, Estes MK Extraintestinal spread of rotavirus infections in children with immunodeficiency. J Pediatr 1992; 120:912-917 [CrossRef][Medline]
43. Parashar UD, Kilgore PE, Holman RC, Clarke MJ, Bresee JS, Glass RI Diarrhea mortality in US infants: influence of birth weight on risk factors for death. Arch Pediatr Adolesc Med 1998; 152:47-51 [Abstract/Free Full Text]
44. Cravioto A, Reyes RE, Trujillo F, Risk of diarrhea during the first year of life associated with initial and subsequent colonization by specific enteropathogens. Am J Epidemiol 1990; 131:886-904 [Abstract/Free Full Text]
45. Reves RR, Hossain MM, Midthun K, An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children: calculation of risk for second episodes using age-specific person-years of observation. Am J Epidemiol 1989; 130:981-988 [Abstract/Free Full Text]
46. Matson DO, O'Ryan ML, Herrer I, Pickering LK, Estes MK Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993; 167:577-583 [Medline]
47. O'Ryan ML, Matson DO, Estes MK, Pickering LK Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections. J Infect Dis 1994; 169:504-511 [Medline]
48. Offit PA Host factors associated with protection against rotavirus disease: the skies are clearing. J Infect Dis 1996; 174(suppl 1):S59-64
49. Jayashree S, Bhan MK, Kumar R, Raj P, Glass R, Bhandari N Serum and salivary antibodies as indicators of rotavirus infection in neonates. J Infect Dis 1988; 158:1117-1120 [Medline]
50. Matsui SM, Mackow ER, Greenberg HB Molecular determinant of rotavirus neutralization and protection. Adv Virus Res 1989; 36:181-214 [Medline]
51. Green KY, Taniguchi K, Mackow ER, Kapikian AZ Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development. J Infect Dis 1990; 161:667-679 [Medline]
52. Ward RL, Bernstein DI Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRv vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine 1995; 13:1226-1232 [CrossRef][Medline]
53. Ward RL. Mechanism of protection against rotavirus in humans and mice. J Infect Dis. 1996;174(suppl 1)S51-S58
54. Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Infect Dis J 1992; 11:535-542 [Medline]
55. Vesikari T Rotavirus vaccines against diarrhoeal disease. Lancet 1997; 350:1538-1541 [CrossRef][Medline]
56. Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996; 174(suppl 1):S65-S72
57. Ing D, Glass RI, Woods PA, Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral polio vaccine. Am J Dis Child 1991; 145:892-897 [Abstract/Free Full Text]
58. Pichichero ME Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. J Infect Dis 1990; 162:753-755 [Medline]
59. Rennels MB, Wasserman SS, Glass RI, Keane VA, US Rotavirus Vaccine Efficacy Group Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children. Pediatrics 1995; 96:1132-1136 [Abstract/Free Full Text]
60. Lanata CF, Midthun K, Black RE, Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174:268-275 [Medline]
61. Linhares AC, Gabbay YB, Mascarenhas JDP, Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull WHO. 1996; 74:491-500 [Medline]
62. Dagan R, Kassis I, Sarov B, Safety and immunogenicity of oral tetravalent human-rhesus reassortant rotavirus in neonates. Pediatr Infect Dis J 1992; 11:991-996 [Medline]
63. Dennehy PH, Rodgers GC Jr, Ward RL, Markwick AJ, Mark M, Zito ET, US Rhesus Rotavirus Vaccine Study Group Comparative evaluation of reactogenicity and immunogenicity of two dosages of oral tetravalent rhesus rotavirus vaccine. Pediatr Infect Dis J 1996; 15:1012-1018 [CrossRef][Medline]
64. Joensuu J Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998; 17:334-340 [CrossRef][Medline]
65. Oshitani H, Kasolo FC, Mpabalwani M, Association of rotavirus and human immunodeficiency virus infection in children hospitalized with acute diarrhea, Lusaka, Zambia. J Infect Dis 1994; 169:897-900 [Medline]
66. Ward RL, Dinsmore AM, Goldberg G, Sander DS, Rappaport RS, Zito ET Shedding of rotavirus following administration of the tetravalent rhesus rotavirus vaccine. Pediatr Infect Dis J 1998; 17:386-390 [CrossRef][Medline]
67. Wright PF, King J, Araki K, Simultaneous administration of two human rhesus rotavirus reassortant strains of VP7 serotypes 1 and 2 specificity to infants and young children. J Infect Dis 1991; 164:271-276 [Medline]
68. Rennels MB, Ward RL, Mack ME, Zito ET, US Rotavirus Vaccine Efficacy Group Concurrent oral poliovirus and rhesus-human reassortant rotavirus association: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. J Infect Dis 1996; 173:306-313 [Medline]
69. Markavick AL, Rennels MB, Zito ET, Oral tetravalent rotavirus vaccine can be successfully coadministered with oral poliovirus vaccine and a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine. Pediatr Infect Dis J 1998; 17:913-918 [CrossRef][Medline]
70. Griffiths RI, Anderson GF, Rowe NR, Economic impact of immunization against rotavirus gastroenteritis. Evidence from a clinical trial. Arch Pediatr Adolesc Med 1995; 149:407-414 [Abstract/Free Full Text]
71. American Academy of Pediatrics, Committee on Pediatric AIDS Evaluation and medical treatment of the HIV-exposed infant. Pediatrics 1997; 99:909-917 [Abstract/Free Full Text]
72. Clark HF, Offit PA, Ellis RW, The development of multivalent bovine rotavirus (Strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174(suppl 1):S73-S80
73. Pickering LK, Morrow AL, Herrera I, Effect of maternal rotavirus immunization on milk and serum antibody titers. J Infect Dis 1995; 172:723-728 [Medline]